Higher Risk of Bleeding in Asians Presenting With ST-Segment Elevation Myocardial Infarction: Analysis of the National Inpatient Sample Database

Abstract

Bleeding is a major complication in patients presenting with ST-segment elevation myocardial infarction (STEMI). Several studies suggested that Asians are more susceptible to bleeding when treated with antiplatelets, anticoagulants, and thrombolytic agents. In our study, we aimed to investigate the association between Asian ethnicity and bleeding events in patients who presented with STEMI. We analyzed the Nationwide Inpatient Sample database from 2002 to 2013 and identified patients hospitalized with a primary diagnosis of STEMI. We compared clinical outcomes between patients of Asian and white ethnicity. Primary outcome was inhospital major bleeding defined as a composite of intracranial hemorrhage and blood transfusions for bleeding events. After exclusions, an estimated 1 695 680 white and 46 563 Asian patients with STEMI were included in the analysis. Asian patients had a higher incidence of inhospital major bleeding (3.6% vs 2.2%, P < .001) without a significant difference in inhospital mortality (9.3% vs 8.7%, P = .06). Asian ethnicity was an independent predictor for major bleeding (estimated odds ratio: 1.32; 95% confidence interval: 1.16-1.51; P < .001). This increased risk of bleeding would warrant further investigation of optimal treatment strategies tailored for patients with STEMI of Asian ethnicity.

Keywords

acute ST-segment elevation myocardial infarction primary percutaneous coronary intervention complications Asian bleeding

Get full access to this article

View all access options for this article.

References

Moscucci

Fox

KAA

Cannon

. Predictors of major bleeding in acute coronary syndromes: the Global Registry of Acute Coronary Events (GRACE). Eur Heart J. 2003;24(20):1815–1823.

Suh

Mehran

Claessen

. Impact of in-hospital major bleeding on late clinical outcomes after primary percutaneous coronary intervention in acute myocardial infarction. J Am Coll Cardiol. 2011;58(17):1750–1756.

Mehta

Cox

Smith

. Race/ethnic differences in the risk of hemorrhagic complications among patients with ischemic stroke receiving thrombolytic therapy. Stroke. 2014;45(8):2263–2269.

Saunders

Ofili

. Epidemiology of atherothrombotic disease and the effectiveness and risks of antiplatelet therapy. Cardiol Rev. 2008;16(2):82–88.

Wang

Chen

Roe

. Comparison of baseline characteristics, treatment patterns, and in-hospital outcomes of Asian versus non-Asian white Americans with non–ST-segment elevation acute coronary syndromes from the CRUSADE quality improvement initiative. Am J Cardiol. 2007;100(3):391–396.

Mehta

Parsons

Peterson

; National Registry of Myocardial Infarction Investigators. Comparison of bleeding and in-hospital mortality in Asian-Americans versus Caucasian-Americans with ST-elevation myocardial infarction receiving reperfusion therapy. Am J Cardiol. 2012;109(7):925–931.

Palaniappan

Araneta

Assimes

. Call to action: cardiovascular disease in Asian Americans: a science advisory from the American Heart Association. Circulation. 2010;122(12):1242–1252.

Overview of the National (Nationwide) Inpatient Sample (NIS). [Internet]. https://www.hcup-us.ahrq.gov/nisoverview.jsp. Accessed September 1, 2017.

Khera

Kolte

Gupta

. Temporal trends and sex differences in revascularization and outcomes of ST-segment elevation myocardial infarction in younger adults in the United States. J Am Coll Cardiol. 2015;66(18):1961–1672.

10.

Elixhauser

Steiner

Harris

Coffey

. Comorbidity measures for use with administrative data. Med Care. 1998;36(1):8–27.

11.

Rao

McCoy

Spertus

. An updated bleeding model to predict the risk of post-procedure bleeding among patients undergoing percutaneous coronary intervention. JACC Cardiovasc Interv. 2013;6(9):897–904.

12.

Baber

Mehran

Giustino

. Coronary thrombosis and major bleeding after PCI with drug-eluting stents: risk scores from PARIS. J Am Coll Cardiol. 2016;67(19):2224–2234.

13.

Mehran

Pocock

Nikolsky

. Impact of bleeding on mortality after percutaneous coronary intervention: results from a patient-level pooled analysis of the REPLACE-2 (Randomized Evaluation of PCI Linking Angiomax to Reduced Clinical Events), ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy), and HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) trials. JACC Cardiovasc Interv. 2011;4(6):654–664.

14.

Mehran

Pocock

Nikolsky

. A risk score to predict bleeding in patients with acute coronary syndromes. J Am Coll Cardiol. 2010;55(23):2556–2566.

15.

Shimada

Nakra

Fox

Kanei

. Relation of race (Asian, African-American, European-American, and Hispanic) to activated clotting time after weight-adjusted bolus of heparin during percutaneous coronary intervention. Am J Cardiol. 2010;105(5):629–632.

16.

Ndrepepa

Fusaro

Cassese

Guerra

Schunkert

Kastrati

. Relation of body mass index to bleeding during percutaneous coronary interventions. Am J Cardiol. 2015;115(4):434–440.

17.

Hillegass

Brott

Chapman

. Relationship between activated clotting time during percutaneous intervention and subsequent bleeding complications. Am Heart J. 2002;144(3):501–507.

18.

Ross

Gao

Coyne

. A randomized trial confirming the efficacy of reduced dose recombinant tissue plasminogen activator in a Chinese myocardial infarction population and demonstrating superiority to usual dose urokinase: the TUCC trial. Am Heart J. 2001;142(2):244–247.

19.

GUSTO Angiographic Investigators. The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction. N Engl J Med. 1993;329(22):1615–1622.

20.

Saito

Isshiki

Kimura

. Efficacy and safety of adjusted-dose prasugrel compared with clopidogrel in Japanese patients with acute coronary syndrome: the PRASFIT-ACS study. Circ J. 2014;78(7):1684–1692.

21.

Wiviott

Braunwald

McCabe

. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007;357(20):2001–2015.

22.

Hiasa

Teng

Emanuelsson

. Pharmacodynamics, pharmacokinetics and safety of ticagrelor in Asian patients with stable coronary artery disease. Cardiovasc Interv Ther. 2014;29(4):324–333.

23.

Xue

Shi

Liu

. Comparison of half- and standard-dose ticagrelor in Chinese patients with NSTE-ACS. Platelets. 2016;27(5):440–445.

24.

Miller

Chu

Hankey

Ries

LAG

. Cancer incidence and mortality patterns among specific Asian and Pacific Islander populations in the U.S. Cancer Causes Control. 2008;19(3):227–256.

25.

Gomez

Noone

Lichtensztajn

. Cancer incidence trends among Asian American populations in the United States, 1990–2008. J Natl Cancer Inst. 2013;105(15):1096–1110.

26.

Schistosomes, liver flukes and Helicobacter pylori. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Lyon, 7–14 June 1994. IARC Monogr Eval Carcinog Risks Hum. 1994;61:1–241.

27.

Huang

Sridhar

Hunt

. Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in peptic-ulcer disease: a meta-analysis. Lancet. 2002;359(9300):14–22.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.11 MB